Could BD be ripe for pick-up?

Becton Dickinson ($BDX) is witnessing successive profit declines for the first time in at least two decades, raising the possibility of an acquisition by the likes of Johnson & Johnson ($JNJ) or private equity firms, according to Haverford Trust and Edward Jones & Co. "Becton is an undervalued company with a tremendous franchise," Hank Smith, chief investment officer at Haverford Trust, said in a telephone interview with Bloomberg. "If Becton gets too much cheaper than this it might very well find itself an acquisition target." News

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.